January 29, 2018
This month, Salil Garg begins his appointment as the Koch Institute’s new Charles W. (1955) and Jennifer C. Johnson Clinical Investigator. Garg’s research is focused on understanding the role of microRNAs and other potential drivers of ‘mutationally bland’ cancers. Since these tumors have few genetic mutations, which makes them unsuitable for genetically-targeted cancer therapies, Garg and his research group are studying other possible avenues for intervention. He is also working with the Anderson and Sharp laboratories to develop a technology for single cell microRNA sequencing as a diagnostic for early cancer detection. Garg, a former Sharp Lab postdoc, is board certified in clinical pathology and completed a fellowship in molecular genetic pathology at Massachusetts General Hospital, where he currently practices. Learn more.